Optimi Health Expands Psychedelic Offerings in Australia with Psilocybin Launch

Optimi Health ( (TSE:OPTI) ) has issued an update.

Optimi Health Corp. has launched its natural psilocybin capsules in Australia for the treatment of Treatment-Resistant Depression under the Authorised Prescriber Scheme. This follows the company’s successful introduction of MDMA sales for PTSD in Australia in 2024. The initial shipment of 1,000 capsules was manufactured at Optimi’s GMP-licensed facility in Canada and distributed through Mind Medicine Australia. This launch marks a significant milestone for Optimi, as both its psilocybin and MDMA products are now available through a regulated government program, enhancing its position in the psychedelic medicine market.

Spark’s Take on TSE:OPTI Stock

According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.

Optimi Health’s overall stock score is primarily influenced by its financial performance, which shows potential but is overshadowed by significant risks due to persistent losses and negative cash flows. Technical analysis provides a moderate positive outlook with short-term bullish signals, while valuation remains a concern due to ongoing losses and lack of dividends.

To see Spark’s full report on TSE:OPTI stock, click here.

More about Optimi Health

Optimi Health Corp. is a leading Canadian producer of prescribed psychedelic treatments for mental health therapies. The company operates as a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer, producing validated MDMA and botanical psilocybin products from its facilities in British Columbia. Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products available for prescription use in Australia and accessible in Canada through the Special Access Program.

Average Trading Volume: 53,199

Technical Sentiment Signal: Sell

Current Market Cap: C$21.74M

See more data about OPTI stock on TipRanks’ Stock Analysis page.